Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

To get a sense of who is truly in control of Pfizer Inc. (NYSE:PFE), it is important to understand the ownership structure of ...

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Employees from the Collegeville location of Pfizer spent some time this week pitching in to renovate a Reading home for a local family in need. The volunteers spent Wednesday hanging drywall at a ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Pfizer Inc. closed 28.57% short of its 52-week high of $31.54, which the company reached on July 30th.

Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...